MORGAN STANLEY PLC/CALL/AMGEN/460/0.1/17.01.25 | Market Closed - Börse Stuttgart 12:30:55 18/05/2024 am IST | ||
| 0.25 EUR | -7.41% |
|
| Current month | +77.30% | ||
| 1 month | +49.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 0.25 | -7.41% |
| 16/24/16 | 0.27 | -6.90% |
| 15/24/15 | 0.29 | +11.54% |
| 14/24/14 | 0.26 | +8.33% |
| 13/24/13 | 0.24 | -7.69% |
Delayed Quote Börse Stuttgart
Last update May 18, 2024 at 12:30 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | ME6QP8 |
| ISIN | DE000ME6QP82 |
| Date issued | 10/01/2024 |
| Strike | 460 $ |
| Maturity | 17/01/2025 (245 Days) |
| Parity | 10 : 1 |
| Emission price | 0.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.36 € |
|---|---|
| Lowest since issue | 0.103 € |
| Spread | 0.03 € |
| Spread % | 10.71% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
312.5
USD
Average target price
314.1
USD
Spread / Average Target
+0.51%
- Stock Market
- Warrants
- Warrant
